Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
暂无分享，去创建一个
A. Kiani | S. Al-Batran | T. Kirchner | G. Seipelt | C. Kahl | L. F. V. Weikersthal | S. Held | L. Miller-Phillips | A. Jagenburg | U. Vehling‐Kaiser | Frank Kullmann | M. Stauch | Markus Moehler | Thomas Decker | Dominik Paul Modest | Andreas Jung | Volker Heinemann | S. Stintzing | Tobias Heintges | Werner Scheithauer | Tobias Heintges | Dominik P Modest | M. Moehler | D. Modest | T. Decker